Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Biogen and Denali Therapeutics announced that BIIB122 (DNL151), a LRRK2 inhibitor, failed to meet primary and secondary endpoints in the Phase 2b LUMA study for early-stage Parkinson's disease. The companies will discontinue development in idiopathic Parkinson's disease, though Denali will continue the Phase 2a BEACON study in LRRK2 variant carriers. The drug demonstrated acceptable safety and >90% kinase inhibition but did not slow disease progression.